Who
Marco Maria Brughera
Director
Company insider
Files Form 4 as: Director, Fennec Pharmaceuticals; Director, Soligenix.
In numbers
- Trades disclosed
- 25
- Buys
- 1
- Sells
- 1
- Bought
- $6,320
- Sold
- $320K
- Companies
- 2
- Companies where not an officer
- 2
- First trade
- 5 Dec 2013
- Last trade
- 15 Sep 2026
- Last filed
- 16 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Sep 2026filed 16 Sep 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $33K15,545 at $2.11 | filing |
| 15 Sep 2026filed 16 Sep 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $160K15,545 at $10.29 | filing |
| 15 Sep 2026filed 16 Sep 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,545 at $0.00 | filing |
| 15 Sep 2026filed 16 Sep 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —15,545 at $0.00 | filing |
| 15 Sep 2026filed 16 Sep 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $33K15,545 at $2.11 | filing |
| 15 Sep 2026filed 16 Sep 2026 | FENC Fennec PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $160K15,545 at $10.29 | filing |
| 10 Jun 2026filed 10 Jun 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $174K20,000 at $8.70 | filing |
| 10 Jun 2026filed 10 Jun 2026 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $174K20,000 at $8.70 | filing |
| 3 Jun 2025filed 4 Jun 2025 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $158K20,000 at $7.88 | filing |
| 15 Aug 2024filed 19 Aug 2024 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | $112K20,000 at $5.58 | filing |
| 12 Jun 2023filed 13 Jun 2023 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 14 Jun 2022filed 16 Jun 2022 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 29 Jun 2021filed 30 Jun 2021 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 13 Aug 2020filed 14 Aug 2020 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 18 Jun 2019filed 19 Jun 2019 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 8 Jun 2018filed 11 Jun 2018 | FENC Fennec Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 8 Jun 2017filed 12 Jun 2017 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,100 at $0.00 | filing |
| 16 Dec 2016filed 20 Dec 2016 | SNGX SoligenixBiotechnology | SEC FORM 4 Bought | $6,3202,000 at $3.16 | filing |
| 16 Dec 2016filed 20 Dec 2016 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code P | —2,500 at $0.00 | filing |
| 16 Jun 2016filed 20 Jun 2016 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,541 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.